Supplementary Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Supplementary Table 1: Detailed assessment of each of the 282 patients. For each of the 282 patients, genomic testing outcome for each modality and each of the eight genomic biomarkers is outlined, as well as KRAS and tissue assessed PD-L1 expression. "-" denotes where mutations in these genes were not assessed. Supplementary Table 2: Comparison of tissue versus cfDNA results for biomarkers in newly diagnosed metastatic NSCLC. For EGFR, four patients had baseline EGFR tissue results that were "negative". Upon review, patients received targeted EGFR testing that did not assess for the mutation identified in cfDNA. Therefore, they were coded as "not assessed" in these expanded tables but were "negative" for the primary endpoint. Supplementary Table 3: Detailed results for patients with positive results. For all 221 patients with a guideline-recommended biomarker detected in cfDNA or tissue, KRAS detected in cfDNA or tissue, or PDL-1 over-expression on tissue Supplementary Table 4: Co-occurring guideline-recommended biomarker and PD-L1 overexpression. Supplementary Table 5: Tissue versus cfDNA analysis Supplementary Table 6: Sites and Principal Investigators for the NILE (Non-invasive versus Invasive Lung Evaluation)